ADME gene polymorphisms do not influence the pharmacokinetics of docetaxel: Results from a population pharmacokinetic study in Indian cancer patients
Abstract Background Pharmacokinetics (PK) of docetaxel is characterized by high inter‐individual variability (IIV). While covariate models that explain the PK variability of docetaxel exist, not much is known about the effects of genetic variations on docetaxel disposition. Methods Fifty patients wi...
Main Authors: | Anand Patil, Bharati Shriyan, Parsshava Mehta, Mrudula Patil, Murari Gurjar, Manjunath Nookala, Vijay Patil, Amit Joshi, Vanita Noronha, Kumar Prabhash, Vikram Gota |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-07-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.4026 |
Similar Items
-
Effect of body mass index on pharmacokinetics of paclitaxel in patients with early breast cancer
by: Vikram Gota, et al.
Published: (2021-05-01) -
ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential
by: Subrata Deb, et al.
Published: (2021-07-01) -
An in vitro ADME and in vivo Pharmacokinetic Study of Novel TB-Active Decoquinate Derivatives
by: Lloyd Tanner, et al.
Published: (2019-02-01) -
Developing nutritional component chrysin as a therapeutic agent: Bioavailability and pharmacokinetics consideration, and ADME mechanisms
by: Song Gao, et al.
Published: (2021-10-01) -
Pharmacokinetics and Toxicities of Oral Docetaxel Formulations Co-Administered with Ritonavir in Phase I Trials
by: Vermunt M, et al.
Published: (2021-01-01)